NN-220 (Somatropin) long-term efficacy and safety investigated for short stature in Noonan Syndrome

Noonan Syndrome is a genetic disorder characterized by distinctive facial features, heart defects, and often, short stature. Growth hormone deficiency or insensitivity is a common contributor to poor growth in these children, necessitating therapeutic intervention. Current standard-of-care often involves growth hormone replacement, but optimal long-term dosing strategies and comprehensive safety profiles specifically for Noonan Syndrome patients remain areas of ongoing research. Understanding the specific needs of this population is crucial for maximizing growth outcomes and minimizing potential side effects.

This clinical trial, conducted in Asia, aims to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin). The study focuses on children with short stature attributed to Noonan Syndrome. The specific route, frequency, duration, and participant numbers are not detailed in the provided abstract, but the trial design is focused on evaluating distinct dosing regimens to establish optimal treatment parameters for this specific patient group.

Results from this ongoing clinical trial are not yet available. The study is actively investigating the long-term efficacy and safety of NN-220 (somatropin) in the target population of children with Noonan Syndrome and short stature. Specific data on growth velocity, height standard deviation scores, or adverse events are pending the completion and analysis of the trial.